Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:BTAI NASDAQ:BYND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.28$2.41$0.86▼$4.46$558.18M0.4617.48 million shs4.50 million shsBTAIBioXcel Therapeutics$1.20-1.6%$1.32$1.01▼$8.08$33.03M0.31921,319 shs478,986 shsBYNDBeyond Meat$0.81-2.9%$0.78$0.50▼$7.69$429.33M2.85109.21 million shs51.53 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+6.05%-16.18%+34.91%+96.55%BTAIBioXcel Therapeutics-1.64%0.00%+13.21%-27.71%-21.57%BYNDBeyond Meat-2.94%-14.77%+35.53%+7.81%-64.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.28$2.41$0.86▼$4.46$558.18M0.4617.48 million shs4.50 million shsBTAIBioXcel Therapeutics$1.20-1.6%$1.32$1.01▼$8.08$33.03M0.31921,319 shs478,986 shsBYNDBeyond Meat$0.81-2.9%$0.78$0.50▼$7.69$429.33M2.85109.21 million shs51.53 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+6.05%-16.18%+34.91%+96.55%BTAIBioXcel Therapeutics-1.64%0.00%+13.21%-27.71%-21.57%BYNDBeyond Meat-2.94%-14.77%+35.53%+7.81%-64.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.73Moderate Buy$8.44270.11% UpsideBTAIBioXcel Therapeutics 2.25Hold$11.00816.67% UpsideBYNDBeyond Meat 1.22Strong Sell$0.832.03% UpsideCurrent Analyst Ratings BreakdownLatest BYND, ALLO, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026ALLOAllogene Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral4/14/2026ALLOAllogene Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.004/14/2026ALLOAllogene Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/14/2026ALLOAllogene Therapeutics ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$5.00 ➝ $8.004/14/2026ALLOAllogene Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.004/13/2026ALLOAllogene Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $10.004/10/2026ALLOAllogene Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K27,909.48N/AN/A$1.30 per share1.75BTAIBioXcel Therapeutics$640K50.78N/AN/A($4.37) per share-0.27BYNDBeyond Meat$275.50M1.51N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.87N/AN/AN/AN/A-57.07%-41.63%5/13/2026 (Estimated)BTAIBioXcel Therapeutics-$69.90M-$6.71N/AN/AN/A-10,887.38%N/A-181.48%N/ABYNDBeyond Meat$219.02M-$2.22N/AN/AN/A54.95%-54.39%32.46%N/ALatest BYND, ALLO, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19N/AN/AN/A$0.00 millionN/A5/6/2026Q1 2026BYNDBeyond Meat-$0.12-$0.10+$0.02-$0.06$58.02 million$58.21 million3/31/2026Q4 2025BYNDBeyond Meat-$0.12-$0.29-$0.17-$0.28$63.00 million$61.59 million3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ABYNDBeyond MeatN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A7.937.93BTAIBioXcel TherapeuticsN/A0.830.82BYNDBeyond MeatN/A2.852.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BTAIBioXcel Therapeutics30.68%BYNDBeyond Meat52.48%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BTAIBioXcel Therapeutics3.70%BYNDBeyond Meat1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310244.82 million212.50 millionOptionableBTAIBioXcel Therapeutics9027.08 million26.07 millionNo DataBYNDBeyond Meat880515.34 million505.55 millionOptionableBYND, ALLO, and BTAI HeadlinesRecent News About These CompaniesBeyond Meat® Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 11 at 6:53 PM | finance.yahoo.comBeyond Meat® Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 11 at 4:05 PM | globenewswire.comA Look At Beyond Meat (BYND) Valuation After Q1 Results And New Functional Beverage PushMay 10 at 9:03 AM | finance.yahoo.comAnalysts Offer Insights on Consumer Goods Companies: Primo Brands (PRMB) and Beyond Meat (BYND)May 8, 2026 | theglobeandmail.comWhy Beyond Meat Stock Skyrocketed 40.3% Last Month but Is Plummeting in MayMay 8, 2026 | fool.com3 AgTech & Food Innovation Stocks to Watch as Food Systems EvolveMay 8, 2026 | finance.yahoo.com3 AgTech & Food Innovation Stocks to Watch as Food Systems EvolveMay 8, 2026 | zacks.comBeyond Meat (BYND) Stock Plunges 14% on Disappointing Q1 Results and Weak Q2 ForecastMay 8, 2026 | blockonomi.comBeyond Meat Shares Pause Following Post-Earnings SelloffMay 8, 2026 | benzinga.comBeyond Meat: Continued Struggles With Structural UnprofitabilityMay 7, 2026 | seekingalpha.comBeyond Meat (BYND) Q1 2026 Earnings TranscriptMay 7, 2026 | fool.comBeyond Meat: Continued DisappointmentMay 7, 2026 | seekingalpha.comBeyond Meat: Q1 Earnings SnapshotMay 7, 2026 | chron.comBYND stock plunges: Weak outlook overshadows first positive gross margin in years — retail loads up anywayMay 7, 2026 | msn.comBeyond Meat’s sales recovery still elusive as another decline predictedMay 7, 2026 | just-food.comJBeyond Meat (BYND) Reports Q1 Loss, Beats Revenue EstimatesMay 6, 2026 | finance.yahoo.comBeyond Meat, Inc. (BYND) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comBeyond Meat (NASDAQ:BYND) Releases Earnings Results, Beats Estimates By $0.02 EPSMay 6, 2026 | marketbeat.comIs a Beyond Meat Stock Buying Frenzy on the Horizon? Here's What Investors Need to Know About the Meme Stock in 2026.May 6, 2026 | fool.comBeyond Meat® Reports First Quarter 2026 Financial ResultsMay 6, 2026 | finance.yahoo.comBeyond Meat (NASDAQ:BYND) Misses Q1 CY2026 Sales Expectations, Stock DropsMay 6, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Alcoa Rebounds as Aluminum Tightens, But a Q1 Miss Tests the RallyBy Jessica Mitacek | April 22, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 2026BYND, ALLO, and BTAI Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.28 0.00 (0.00%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$2.30 +0.02 (+0.66%) As of 05/11/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.BioXcel Therapeutics NASDAQ:BTAI$1.20 -0.02 (-1.64%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.67%) As of 05/11/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Beyond Meat NASDAQ:BYND$0.81 -0.02 (-2.94%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$0.80 -0.01 (-0.94%) As of 05/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beyond Meat, Inc., a plant-based meat company, develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club stores, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was incorporated in 2008 and is headquartered in El Segundo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
